|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
CNS cancer
Hypo-trimethylation of
Histone
H3 Lysine 4 and Hyper-tri/dimethylation of
Histone
H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma
Hoon Gi Kim, Minseok S. Kim, Young Sam Lee, Eun Hee Lee, Dae Cheol Kim, Sung-Hun Lee, Young Zoon Kim
Cancer Res Treat.
2022;54(3):690-708. Published online November 17, 2021 DOI:
https://doi.org/10.4143/crt.2021.1121
Web of Science 4
Crossref 4
Lung and Thoracic cancer
Histone
Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer
Hyun-Seock Shin, Juwhan Choi, Jinhwan Lee, Sung Yong Lee
Cancer Res Treat.
2022;54(2):458-468. Published online September 10, 2021 DOI:
https://doi.org/10.4143/crt.2021.425
Web of Science 7
Crossref 8
Induction of Apoptosis in Intestinal Toxicity to a
Histone
Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
Erta Kalanxhi, Karianne Risberg, Imon S. Barua, Svein Dueland, Stein Waagene, Solveig Norheim Andersen, Solveig J. Pettersen, Jessica M. Lindvall, Kathrine Røe Redalen, Kjersti Flatmark, Anne Hansen Ree
Cancer Res Treat.
2017;49(2):374-386. Published online July 28, 2016 DOI:
https://doi.org/10.4143/crt.2016.080
Web of Science 4
Crossref 4
Isotype-Specific Inhibition of
Histone
Deacetylases: Identification of Optimal Targets for Radiosensitization
Jin Ho Kim, Sung Ho Moon, Mina No, Jae Jin Kim, Eun Jung Choi, Bong Jun Cho, Jae Sung Kim, Il Han Kim, In Ah Kim
Cancer Res Treat.
2016;48(3):1130-1140. Published online November 17, 2015 DOI:
https://doi.org/10.4143/crt.2015.206
Web of Science 9
Crossref 9
Aberrant Epigenetic Modifications of
LPHN2 Function as a Potential Cisplatin-Specific Biomarker for Human Gastrointestinal Cancer
Mi-Seong Jeon, Sang-Hyun Song, Jiyeon Yun, Jee-Youn Kang, Hwang-Phill Kim, Sae-Won Han, Tae-You Kim
Cancer Res Treat.
2016;48(2):676-686. Published online September 22, 2015 DOI:
https://doi.org/10.4143/crt.2015.153
Web of Science 14
Crossref 10
Sequence-Dependent Radiosensitization of
Histone
Deacetylase Inhibitors Trichostatin A and SK-7041
Jin Ho Kim, Il Han Kim, Jin Hee Shin, Hak Jae Kim, In Ah Kim
Cancer Res Treat.
2013;45(4):334-342. Published online December 31, 2013 DOI:
https://doi.org/10.4143/crt.2013.45.4.334
Web of Science 5
Crossref 7
A
Histone
Deacetylase Inhibitor, Trichostatin A, Enhances Radiosensitivity by Abrogating G2/M Arrest in Human Carcinoma Cells
In Ah Kim, Jin Ho Kim, Jin Hee Shin, Il Han Kim, Jae Sung Kim, Hong-Gyun Wu, Eui Kyu Chie, Yong Ho Kim, Bo-Kyung Kim, Semie Hong, Seok Won Park, Sung Whan Ha, Charn Il Park
Cancer Res Treat.
2005;37(2):122-128. Published online April 30, 2005 DOI:
https://doi.org/10.4143/crt.2005.37.2.122
Crossref 15
Transcriptional Regulation of H2B
Histone
Gene Expression by Nocodazole in HL-60 Cells
Kyu Lim, Ye Gi Hong, Myung Sun Lee, Mee Young Son, Kyung Ah Yun, Jong Il Park, Wan Hee Yoon, Sung Kiel Park, Byung Doo Hwang
J Korean Cancer Assoc.
2000;32(2):407-416.
Prognostic Significance of Tumor Angiogenesis , Metastasis Regulation Gene Protein ( NDP-K / nm23 ) and
Histone
mRNA Expression in Breast Cancer
Hye Rim Park, Young Sik Kim, In Sun Kim
J Korean Cancer Assoc.
1995;27(2):253-265.
Studies on the H2B
Histone
, c-Myc and DNA Topoisomerase 1 Gene Expression during HL - 60 Differentiation by All - Trans Retinoic Acid
Kyu Lim, Jeong Dong Park, Byung Han Choi, Young Jin Lee, Kye Young Kim, Myung Sun Lee, Eun Mi Chang, Sam Yong Kim, Gi Ryang Kweon, Sang Tae Kwak, Byung Doo Hwang
J Korean Cancer Assoc.
1994;26(2):285-296.
1
Journal Impact Factor 4.6